ProMIS Reports Encouraging Safety and Biomarker Results for Alzheimer’s Candidate PMN310
Blinded six-month interim results show no ARIA-E with PMN310, favorable safety in APOE4 carriers, early biomarker movement, and analyst upgrades.
/ 492 items
#XY Event-Driven Stocks↓
Altimmune’s Experimental Drug Cuts Heavy Drinking Days in Key Phase 2 Trial
Altimmune’s experimental drug cut heavy drinking and helped weight loss in a mid-stage alcohol use disorder trial. Next: FDA meeting.
J&J Agrees to $5.5 Billion Settlement to End Decade of Talc Cancer Lawsuits
Johnson & Johnson agrees to pay $5.5 billion to settle ~76,000 lawsuits claiming its talc baby powder caused ovarian cancer, ending 10+ years of litigation.
Legend Biotech CEO Abruptly Resigns Without Permanent Successor
Legend Biotech CEO Ying Huang steps down. Carvykti president Alan Bash named interim CEO while search for permanent successor continues.
Morgan Stanley on Sarepta’s CEO Switch: Clear Handover Is Positive, but DMD Challenges Linger
Michael Severino becomes Sarepta’s new CEO as Doug Ingram retires.
Capricor Shares Plunge After FDA Briefing Documents Raise Doubts on Deramiocel
FDA briefing documents for Capricor’s deramiocel question effectiveness and highlight safety risks ahead of the July 29 advisory committee.